You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

ADENOSINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Adenosine patents expire, and when can generic versions of Adenosine launch?

Adenosine is a drug marketed by Am Regent, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Mylan Labs Ltd, Norvium Bioscience, Rising, Teva Pharms Usa, Wockhardt, Avet Lifesciences, Eugia Pharma, Hospira, Meitheal, and Mylan Asi. and is included in twenty-one NDAs.

The generic ingredient in ADENOSINE is adenosine. There are twenty-six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adenosine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Adenosine

A generic version of ADENOSINE was approved as adenosine by HIKMA on June 16th, 2004.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADENOSINE?
  • What are the global sales for ADENOSINE?
  • What is Average Wholesale Price for ADENOSINE?
Drug patent expirations by year for ADENOSINE
Drug Prices for ADENOSINE

See drug prices for ADENOSINE

Recent Clinical Trials for ADENOSINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
MedSIRPhase 2
The University of Texas Health Science Center, HoustonPhase 4
Society of Cardiovascular AnesthesiologistsPhase 4

See all ADENOSINE clinical trials

Pharmacology for ADENOSINE
Medical Subject Heading (MeSH) Categories for ADENOSINE
Anatomical Therapeutic Chemical (ATC) Classes for ADENOSINE
Paragraph IV (Patent) Challenges for ADENOSINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ADENOSCAN Injection adenosine 3 mg/mL, 20 mL and 30 mL vials 020059 1 2005-04-18

US Patents and Regulatory Information for ADENOSINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rising ADENOSINE adenosine SOLUTION;INTRAVENOUS 090450-002 Oct 2, 2014 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Am Regent ADENOSINE adenosine INJECTABLE;INJECTION 090010-001 Apr 28, 2009 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Eugia Pharma ADENOSINE adenosine SOLUTION;INTRAVENOUS 205331-002 Nov 2, 2017 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Meitheal ADENOSINE adenosine SOLUTION;INTRAVENOUS 077425-002 Aug 29, 2013 AP RX No Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hikma ADENOSINE adenosine INJECTABLE;INJECTION 076500-001 Jun 16, 2004 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Gland Pharma Ltd ADENOSINE adenosine INJECTABLE;INJECTION 077283-001 Jun 14, 2007 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Teva Pharms Usa ADENOSINE adenosine INJECTABLE;INJECTION 076564-001 Jun 16, 2004 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

ADENOSINE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Adenosine Injections

Introduction to Adenosine Injections

Adenosine injections have become a crucial component in the management of cardiac arrhythmias, particularly in emergency medicine. Here, we will delve into the market dynamics, financial trajectory, and key factors influencing the growth of the adenosine injection market.

Market Overview

The global adenosine injection market is poised for significant growth, driven by several key factors. The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.17% from 2024 to 2030, reaching a market size of US$ 2.59 billion by 2030[1][3].

Drivers of Market Growth

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases such as cardiovascular diseases, cystic fibrosis, lung cancer, and atrial fibrillation is a major driver of the market. According to the American Heart Association, 40% of people in the U.S. will be affected by heart disease by 2030, which is likely to increase the number of cardiac surgeries and the demand for adenosine injections[1].

Aging Population and Increased Healthcare Spending

The aging population and increased healthcare spending are significant drivers. As the global population ages, the incidence of heart-related conditions increases, leading to a higher demand for adenosine injections. Increased healthcare spending and advancements in medical technology also contribute to market growth[3].

Awareness and R&D Activities

Rising awareness about cardiac conditions and ongoing research and development (R&D) activities are enhancing market growth. The development of new and advanced products, such as prefilled syringes and wearable devices, is further boosting the market[1][3].

Regional Analysis

North America

North America is expected to hold a dominant share of the global adenosine injection market during the forecast period. This dominance is attributed to the rising number of people undergoing cardiac surgeries, the growing geriatric population, and increased funding for healthcare research and development[1].

Asia Pacific

The Asia Pacific region is anticipated to be the fastest-growing region, driven by improved medical infrastructure, a large target population, increased awareness, and the development of innovative and cost-effective products. Countries such as Japan, China, India, and South Korea are expected to drive this growth[1].

Applications and End-Users

Applications

Adenosine injections are primarily used in the treatment of paroxysmal supraventricular tachycardia (PSVT) and as an adjunct to thallium-201 in myocardial perfusion scintigraphy. They are also used in various surgical procedures, including general surgery, cardiac surgery, cancer surgery, and neurological surgery[1][5].

End-Users

The key end-users of adenosine injections include diagnostics laboratories, pathology labs, hospitals, and life sciences and research labs. The demand from these sectors is driven by the need for rapid and effective solutions for managing cardiac arrhythmias[1].

Competitive Landscape

The global adenosine injection market is competitive, with several key players such as Torrent Laboratories, Sun Pharmaceuticals, Celon Laboratories, Pfizer, Teva Pharmaceuticals, and others. These companies are focusing on innovation, manufacturing, and global distribution to maintain their market share[1].

Financial Trajectory

Market Size and Growth

The adenosine injection market was valued at US$ 1.82 billion in 2023 and is expected to reach US$ 2.59 billion by 2030, growing at a CAGR of 5.17% during the forecast period[1].

Investment Opportunities

The market offers significant investment opportunities, particularly in innovation, manufacturing, and global distribution channels. Investors can tap into this growing market by focusing on the development of new products and technologies, such as prefilled syringes and wearable devices[3].

Challenges and Restraints

Side Effects

One of the major restraints on the market is the potential side effects of adenosine injections, such as triggering convulsions in patients. The administration of adenosine must be carefully monitored to mitigate these risks[1].

Role in Emergency Medicine

Adenosine injections are revolutionizing emergency medicine by providing a fast, effective, and affordable solution for managing life-threatening cardiac arrhythmias. Their rapid onset of action and ability to stabilize heart rhythms within seconds make them indispensable in emergency departments and pre-hospital settings[3].

Clinical Trials and R&D

There is ongoing research and development in the field of adenosine receptors, with a focus on developing subtype-selective agonists and antagonists. Clinical trials are underway for various indications, including inflammatory diseases, neurodegenerative afflictions, and cancer. The recent approval of the A2A adenosine receptor antagonist istradefylline for Parkinson’s disease has energized the field and opened up new avenues for research[2].

Key Takeaways

  • The global adenosine injection market is expected to grow at a CAGR of 5.17% from 2024 to 2030.
  • The market is driven by the rising prevalence of chronic diseases, an aging population, and increased healthcare spending.
  • North America and the Asia Pacific region are key markets, with the latter expected to be the fastest-growing.
  • Adenosine injections are crucial in emergency medicine for managing cardiac arrhythmias.
  • Side effects and careful administration are critical considerations.
  • Ongoing R&D activities and clinical trials are expanding the therapeutic potential of adenosine.

FAQs

What is the expected CAGR of the global adenosine injection market from 2024 to 2030?

The global adenosine injection market is expected to grow at a CAGR of 5.17% from 2024 to 2030[1].

Which region is expected to dominate the global adenosine injection market?

North America is expected to hold a dominant share of the global adenosine injection market during the forecast period[1].

What are the primary applications of adenosine injections?

Adenosine injections are primarily used to treat paroxysmal supraventricular tachycardia (PSVT) and as an adjunct to thallium-201 in myocardial perfusion scintigraphy[5].

Who are the key players in the global adenosine injection market?

Key players include Torrent Laboratories, Sun Pharmaceuticals, Celon Laboratories, Pfizer, Teva Pharmaceuticals, and others[1].

What are the potential side effects of adenosine injections?

Adenosine injections can trigger side effects such as convulsions in patients, requiring careful monitoring during administration[1].

Sources

  1. Maximize Market Research: Adenosine Injection Market - Industry Analysis, Forecast 2030.
  2. Pharmacological Reviews: International Union of Basic and Clinical Pharmacology. CXII.
  3. Market Research Intellect: The Role of Adenosine Injections in Revolutionizing Emergency Medicine.
  4. Pharmaceutical Technology: Adenosine Receptor A1 drugs in development, 2024.
  5. DrugBank: Adenosine: Uses, Interactions, Mechanism of Action.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.